Probiotic-based immune enhancement therapy: Probiotic Clostridium butyricum MIYAIRI 588 (CBM588) increases SOX2 expression, and promotes innate immunity against bacterial infection, via down-regulation of its target gene, 12/March/2019, 9.41 am

Ribonucleic acid-based therapy for Diabetes Mellitus: LncRNA H19 augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM, via upregulation of its target gene, 12/March/2019, 9.27 am
March 12, 2019
Repurposing the antihyperlipidemic drug Atorvastatin into an anti-HIV agent: Atorvastatin (trade name: Lipitor), a medication prescribed to lower cholesterol and triglyceride, increases Heme oxygenase 2 (HO-2) expression, blocks N-myristoylation of HIV-1 Gag protein, disrupts HIV-1 budding, and restricts HIV-1 production, via upregulation of its target gene, 12/March/2019, 9.51 am
March 12, 2019
Show all

Introduction: What they say:  

A recent study from the Institute of Biophysics, Chinese Academy of Sciences, Beijing, China shows that “Sox2 functions as a sequence-specific DNA sensor in neutrophils to initiate innate immunity against microbial infection.” This study was published, in the 2 March 2015 issue of the Journal “Nature Immunology” [the number one journal in immunological research with an impact factor of  24.973], by Drs. Zusen Fan, Xia and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that: Probiotic-based immune enhancement therapy: Probiotic Clostridium butyricum MIYAIRI 588 (CBM588) increases SOX2 expression, and promotes innate immunity against bacterial infection, via down-regulation of its target gene


From Research Findings to Therapeutic Opportunity:

This study suggests, for the first time, Probiotic Clostridium butyricum MIYAIRI 588 (CBM588)by decreasing the expression of its target gene, it may : (1) increase the expression of Sox2; (2) increase the ability of Sox2 to recognize bacterial DNA in the cytoplasm; and (3) promote innate immunity against bacterial infection. 

Figure 1. Probiotic-based immune enhancement therapy. Probiotic Clostridium butyricum MIYAIRI 588, by increasing the expression of its target genes, it increases the expression of Sox-2 and its downstream components in the signaling pathway. And, thereby, promotes anit-bacterial immunity.

Figure 2. Probiotic Clostridium butyricum MIYAIRI 588 may increase resistance against bacterial infection through induction of Sox2

Together,pharmacological formulations encompassing “Clostridium butyricum MIYAIRI 588,  either alone or in combination with other drugs,” may be used to (1) enhance innate immunity against bacterial infection; and (2) promote bacterial resistance (figs. 1-2). 


Details of the research findings

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does probiotic Clostridium butyricum MIYAIRI 588 (CBM588) enhance innate immunity against bacterial infections?

Amount: $750

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

CitationBoominathan, L., Probiotic-based immune enhancement therapy: Probiotic Clostridium butyricum MIYAIRI 588 (CBM588) increases SOX2 expression, and promotes innate immunity against bacterial infection, via down-regulation of its target gene, 12/March/2019, 9.41 am,  Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.